Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA warning on home diagnostic kits

This article was originally published in The Tan Sheet

Executive Summary

Pregnancy Test and Rapid HIV Test Kit marketed by the Canadian firm Globus Media are among the unapproved diagnostic products being sold by the company and should not be purchased, FDA says in a Feb. 7 consumer warning. The other six illegal kits are an HCG urine test and tests for syphilis, cocaine, marijuana, amphetamine and dengue fever. Use of the kits may produce false results that could "lead to significant adverse health consequences" if those who test negative do not seek medical treatment or spread a virus to others, the agency notes. The tests have been marketed nationwide through websites. Anyone who has used one of the kits "should be retested using valid test methods," FDA says...

You may also be interested in...

OraSure Seeks Regulatory Feedback For Marketing Home-Use HIV Test

OraSure Technologies will seek guidance from FDA's Blood Product's Advisory Committee on making its OraQuick Advance oral fluid HIV test available over the counter for use in the home

Interview: OurCrowd CEO Jon Medved On Israel’s Medtech “Boomtown”

With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts